PDF(Pubmed)
Abstract：
BACKGROUND: We previously identified a genetic subtype (C4) of type 2 diabetes (T2D), benefitting from intensive glycemia treatment in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Here, we characterized the population of patients that met the C4 criteria in the UKBiobank cohort.
METHODS: Using our polygenic score (PS), we identified C4 individuals in the UKBiobank and tested C4 status with risk of developing T2D, cardiovascular disease (CVD) outcomes, and differences in T2D medications.
RESULTS: C4 individuals were less likely to develop T2D, were slightly older at T2D diagnosis, had lower HbA1c values, and were less likely to be prescribed T2D medications (P < .05). Genetic variants in MAS1 and IGF2R, major components of the C4 PS, were associated with fewer overall T2D prescriptions.
CONCLUSIONS: We have confirmed C4 individuals are a lower risk subpopulation of patients with T2D.
METHODS: Using our polygenic score (PS), we identified C4 individuals in the UKBiobank and tested C4 status with risk of developing T2D, cardiovascular disease (CVD) outcomes, and differences in T2D medications.
RESULTS: C4 individuals were less likely to develop T2D, were slightly older at T2D diagnosis, had lower HbA1c values, and were less likely to be prescribed T2D medications (P < .05). Genetic variants in MAS1 and IGF2R, major components of the C4 PS, were associated with fewer overall T2D prescriptions.
CONCLUSIONS: We have confirmed C4 individuals are a lower risk subpopulation of patients with T2D.
摘要：
背景：我们先前确定了2型糖尿病（T2D）的遗传亚型（C4），在控制糖尿病心血管风险的行动（ACCORD）试验中受益于强化血糖治疗。这里,我们对UKBiobank队列中符合C4标准的患者人群进行了表征.
方法：使用我们的多基因评分（PS），我们在UKBiobank中确定了C4个体，并测试了具有发展为T2D的风险的C4状态，心血管疾病（CVD）结局，以及T2D药物的差异。
结果：C4个体不太可能发生T2D，在T2D诊断时年龄稍大，HbA1c值较低，并且不太可能服用T2D药物（P<0.05）。MAS1和IGF2R的遗传变异，C4PS的主要成分，与总体T2D处方较少相关。
结论：我们已经证实C4个体是T2D患者的低风险亚群。
方法：使用我们的多基因评分（PS），我们在UKBiobank中确定了C4个体，并测试了具有发展为T2D的风险的C4状态，心血管疾病（CVD）结局，以及T2D药物的差异。
结果：C4个体不太可能发生T2D，在T2D诊断时年龄稍大，HbA1c值较低，并且不太可能服用T2D药物（P<0.05）。MAS1和IGF2R的遗传变异，C4PS的主要成分，与总体T2D处方较少相关。
结论：我们已经证实C4个体是T2D患者的低风险亚群。
